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Abstract
BACKGROUND: Ovarian cancer is the most common cause of death among gynecologic malignancies. Poor 
prognosis is mainly due to the high incidence of advanced stage at the time of diagnosis as well as low estrogen 
receptor (ER) and progesterone receptor (PR) expression. Based on it, further understanding is needed to predict 
the course of disease. 
AIM: This study aims to evaluate the expression of ER and PR with the stages of endometrioid-type ovarian 
carcinoma as the more frequent type carcinoma at Sanglah General Hospital, Bali.
METHODS: An analytical cross-sectional study was conducted among 36 samples of endometrioid-type ovarian 
carcinoma examined at Anatomical Pathology Laboratory, Faculty of Medicine, Udayana University/Sanglah General 
Hospital, Denpasar. The histopathological diagnosis, grade, and tumor size, as well as determination on hematoxylin-
eosin staining were assessed. The expression of ER and PR was examined using immunohistochemical stain. Data 
were analyzed using the SPSS version 15 software for risk analysis and p < 0.05 was assumed statistically significant.
RESULTS: Most of the samples were from 41 to 50 years of age group (41.7%) and the average age was 51.1 ± 
9.80 years old. Based on the degree of differentiation, Grade 2 was the most common cases (38.9%). However, the 
tumor size assessment revealed that T3 was predominant (41.7%). Positive ER and PR expressions were obtained 
in 18 samples (50.0%) and 14 samples (38.9%), respectively. Fisher’s exact test showed a significant association 
between ER expression with grade (odds ratio [OR]: 6.25; 95% confidence interval [CI] 1.327–29.432; p = 0.018) 
and tumor size (OR: 4.375; 95% CI 1.027–18.629; p = 0.043). A similar findings also found in PR expression with 
grade (OR: 15.60; 95% CI 1.728–140.829; p = 0.004) and tumor size (OR: 6.12; 95% CI 1.394–26.876; p = 0.016).
CONCLUSION: ER and PR expressions are significantly associated with grade and tumor size in the endometrioid-
type ovarian carcinoma.
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Introduction
Ovarian cancer is the seventh most cancer, 
occurring around 3% of all malignancies in the woman 
and is the leading cause of death in gynecological 
malignancies [1]. Among malignancies in the female 
genital tract, ovarian cancer ranks after cervical 
and endometrial cancer. It is estimated that around 
190,000 new cases and 114,000 deaths from ovarian 
cancer occur every year [2]. One thing that causes 
poor prognosis is the high incidence of tumors at an 
advanced stage when the diagnosis is established, 
which is about 75% of all patients diagnosed at FIGO 
Stage III or IV, as a staging system in ovarian cancer [2]. 
A more in-depth study about the prognostic factors as 
well as more integrated patient management is needed.
There are various theories of tumorigenesis of 
ovarian cancer, one of which is hormonal effects [3], [4], [5]. 
Several factors have been evaluated from hematological 
markers until particular surface receptor expression 
to assess the prognostic of cancers [4], [5]. The study 
on estrogen receptor (ER) and progesterone receptor 
(PR) in breast and endometrial malignancies has been 
carried out and has been known to have relevance in 
therapy and prognostic [4]. This is different from ovarian 
cancer, where there is still a lack of data regarding ER 
and PR expression to ovarian cancer, and the results are 
even contradictory [6]. The clinical trial study, subtype 
determination, and biomarker status are needed to 
determine whether hormone receptor status in ovarian 
carcinoma can predict the response to endocrine therapy 
whether it can be used as a guideline for personal therapy 
for ovarian cancer [7]. Only 15%–18% of ovarian cancers 
with ER-positive responds to anti-estrogen treatment 
by inhibiting estrogen binding with ER. On the contrary 
in breast cancer, anti-estrogen treatment is effective in 
about 50% of patients. The most common mechanism 
for causing resistance to anti-estrogen therapy is the 
absence of ER [2]. Different study designs and sample 
sizes could cause these discrepancies.
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The ovary has three main histological 
compartments, namely: Mullerian or coelomic surface 
epithelium, sex cord-stromal cell, and pluripotent 
germinal cells [8]. In developing countries, more 
than 90% of malignant ovarian tumor origin from 
epithelium, 5%–6% sex cord-stromal tumor, and 
2%–3% from germinal cells. Epithelial ovarian 
cancer is a heterogeneous disease, with several 
histological subtypes, which differ in terms of origin, 
pathogenesis, molecular changes, risk factors, gene 
expression, and prognosis [3], [7], [9]. Based on 
histopathology evaluation, ovarian neoplasms that 
fall into the category of surface epithelial tumors are 
serous tumor, mucinous tumor, endometrioid tumor, 
clear cell tumor, Brenner tumor, seromucinous tumor, 
and undifferentiated carcinoma [10]. Besides, the 
ovarian carcinoma also could be classified based 
on the expression of particular surface receptor. The 
previous study found that ER and PR expression 
differed between ovarian cancer subtypes [6], [11]. 
The proportion of tumors that were positive for 
PR was found to be highest in endometrioid-type 
carcinoma (67%), whereas positive ER with positive 
PR was also found to be highest in the endometrioid 
type (82%) [11]. However, the study did not assess 
further the relationship between positive expression 
of PR and ER in the progression of endometrioid-
type carcinoma. The expression of ER and PR is 
different in various grades and stage ovarian cancer. 
ER and PR expressions are also can be used as an 
independent prognostic marker for patient survival, 
i.e. the positive expression can increase the patient 
survival rate [11].
Based on those as mentioned earlier, the 
purpose of this study is to investigate the association 
between the expression of ER and PR with the severity 
of endometrioid-type ovarian carcinoma at Sanglah 
General Hospital, Bali, Indonesia, as a preliminary 
study.
Materials and Methods
Study design
A cross-sectional analytic observational study 
was conducted during the year 2018 among surgical 
tissue of respondents who were diagnosed with 
endometrioid-type ovarian carcinoma. All of patients 
who had undergone biopsy were taken based on 
medical records using consecutive sampling technique 
approach.
Sample collection process
The samples of this study were surgical tissue 
of patients with endometrioid-type ovarian carcinoma, 
whose tissues were examined at the Anatomical 
Pathology Department, Faculty of Medicine, Udayana 
University/Sanglah General Hospital which corresponds 
to inclusion and exclusion criteria. Samples were 
collected on a consecutive basis until the required 
samples size was met. There were 36 samples enrolled 
in this study.
Histopathological examination
This study was conducted at the Anatomical 
Pathology Department, Faculty of Medicine, Udayana 
University/Sanglah General Hospital. The specimens 
were consisted of histological preparations derived from 
patients treated for ovarian carcinoma. The samples 
of specimen were fixed in 10% buffered formalin 
phosphate. Paraffin blocks were cut into sections with 
a thickness about 3–4 µm. The collecting sections were 
stained with hematoxylin and eosin to identify the type 
of carcinoma (WHO classification) and histological 
grade of malignancy. All specimens were evaluated 
using light microscopy in ×100 magnification. Degree 
of differentiation in this study was evaluated into two 
categories: Low grade (≤Grade 2) and high grade 
(>Grade 2). In addition, the tumor size also divided into 
two categories: T1 and ≥T2.
Immunohistochemical evaluation of ER 
and PR
The paraffin-embedded tissues from 
surgery tissue of patients that have been diagnosed 
histopathologically with endometrioid-type ovarian 
carcinoma were examined immunohistochemically. 
To determine the expression of steroid receptors, 
monoclonal antibodies against receptors for estrogen 
(Cell Marque Rabbit Monoclonal Antibody ER 
(EP1), 1:50 dilution) and PR (Cell Marque Rabbit 
Monoclonal Antibody PR (Y85) Vantagebio, 1:400 
dilution) were used. The following steps were as 
follows: (1) Incubated the section in an incubator 
at 60°C overnight and then dewaxed, (2) reveal 
the epitope by heating slides in a buffer for 40 min, 
(3) the preparations were left at room temperature 
for 20 min, (4) preparations were rinsed in buffer, 
and then, endogenous peroxidase was blocked in 
3% H2O2 and incubated with an appropriate antibody, 
(5) preparations were rinsed in a buffer for 10 min 
and then incubated with the reagent (Visualization 
Reagent) for 30 min, (6) washed in TBS (Tris-buffered 
saline, Code: S1968) pH 7.5–7.6 for 10–15 min, and 
(7) incubated with 3,3’-diaminobenzidine (substrate – 
chromogen solution) for 10 min to visualize the color 
reaction.
The results interpretation was determined 
using Allred SCORING SYSTEM. As per the Allred 
score for ER and PR nuclear positivity, the proportion 
score (PS) (0–5) and the % positive tumor cells are, 
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respectively, 0 (0%), 1 (<1%), 2 (1–10%), 3 (11–33%), 
4 (34–66%), and 5 (67–100%). The intensity of staining 
(IS) for the nuclear positivity of the cells graded as 0, 
1, 2, and 3 was as none, mild, moderate, and strong, 
respectively. Hence, the total scores for ER and PR 
are given as TS = PS + IS. TS 0 and 2 are negative 
scores, and 3, 4, 5, 6, 7, and 8 are positive scores. 
In summary, the positive expression of ER and PR 
receptor on endometrioid-type ovarian carcinoma in 
this study was investigated, if >10% positive cells after 
IHC per field was viewed.  Less than 10% indicate for 
negative expression.
Statistical analysis
A descriptive characteristic of the data subject 
was tabulated. The Shapiro–Wilk test was performed to 
determine the normality of the data, and the Levene’s 
t-test was performed to find homogeneity and equality. 
Due to data were not normally distributed, a Fisher’s 
exact test was performed to determine the correlation 
between ER and PR expressions with a degree of 
differentiation and the size of the tumor as well as risk 
analyses using odds ratio (OR). Statistical significance 
was determined if p < 0.05 with 95% confidence 
interval (CI).
Results
The characteristics of the respondents with 
endometrioid-type ovarian carcinoma used in this 
study are summarized in Table 1 based on age, 
degree of differentiation, tumor size, and expression of 
ER and PR. The study found that the average age of 
respondents was 51.08 ± 9.80 years old. Furthermore, 
it can also be classified into several groups, whereas 
the group of 41–50 years old was predominant 
(41.7%). Based on the degree of differentiation, 
Grade 3 was the most common cases (41.7%). In 
addition, the tumor size also had the highest number in 
T3 group (41.7%) followed by 50% for ER expression 
and 38.9% for PR expression (38.9%). Normality test 
using Shapiro–Wilk suggested that all of the variables 
mentioned above, except for age, were not normally 
distributed (p < 0.05).
The degree of differentiation was reclassified 
further into ≤Grade 2 and >Grade 2 to determine the 
risk between ER and PR expression with the grading of 
endometrioid-type ovarian carcinoma using OR. There 
was 15 (65.2%) positive ER expression in Grade 2 or 
below and approximately 13 (56.5%) of cases also 
showing a positive PR expression. Risk analysis was 
conducted using Fisher’s exact test and OR due to 
data was not normally distributed. The recent findings 
revealed that ER and PR expressions were significantly 
higher in the Grade 2 or below (p < 0.05) where ER 
expression was 6.25 (95% CI: 1.327–29.432) times 
higher in the low grade (≤Grade 2) compared with 
high grade (>Grade 2) degree of differentiation group. 
A similar result was also found in PR expression 
whereas 15.60 (1.728–140.829) times higher in 
Grade 2 or below (Table 2).
Table 1: Baseline characteristic of respondents with 
endometrioid-type ovarian carcinoma
Variables Assessment p-value
n(%) Mean±SD
Age (years) Classification of age (years) 51.08±9.80
31–40 3 (8.3) 0.318a
41–50 15 (41.7)
51–60 13 (36.1)
61–70 2 (5.6)
71–80 3 (8.3)
Grading differentiation (%)
Grade 1 9 (25.0) 0.000a
Grade 2 14 (38.9)
Grade 3 13 (41.7)
Tumor size (%)
T1 14 (38.9) 0.000a
T2 7 (19.4)
T3 15 (41.7)
Estrogen receptor
Positive 18 (50.0) 0.000a
Negative 18 (50.0)
Progesterone receptor
Positive 14 (38.9) 0.000a
Negative 22 (61.1)
aShapiro–Wilk: Data were normally distributed if p>0.05.
The tumor size was also reclassified into T1 and 
≥T2 to evaluate the risk analysis between tumor size and 
the expression of estrogen or PR, respectively. There 
were 15 (65.2%) samples as positive ER expression 
and about 13 (56.5%) cases as positive PR expression. 
A recent study also found that ER and PR expressions 
were also statistically significant higher expressed in T1 
tumor size compared with T2 or above (p < 0.05). Positive 
ER and PR expressions were 4.375 (1.027–18.629) and 
6.12 (1.394–26.876) times higher in T1 tumor size group 
compared to the T2 tumor size (Table 3).
Table 2: Risk analysis between ER and PR expression to the 
degree of differentiation
Parameters Degree of 
differentiation n (%)
OR 95% confidence 
interval
p-value
≤Grade 2 >Grade 2 Lower Upper
Estrogen receptor
Positive expression (+) 15 (65.2) 3 (23.1) 6.25 1.327 29.432 0.018*
Negative expression (−) 8 (34.8) 10 (76.9)
Progesterone receptor
Positive expression (+) 13 (56.5) 1 (7.7) 15.60 1.728 140.829 0.004*
Negative expression (−) 10 (43.5) 12 (92.3)
*Fisher’s exact test: Statistically significant if p<0.05; OR: Odds ratio, PR: Progesterone receptor, 
ER: Estrogen receptor.
Histopathological assessment was carried out 
using hematoxylin-eosin H and E). The sample with H 
Table 3: Relationship between ER and PR expression to the 
tumor size
Parameters Tumor size n (%) OR 95% confidence 
interval
p-value
T1 ≥T2 Lower Upper
Estrogen receptor
Positive expression (+) 10 (71.4) 8 (36.4) 4.375 1.027 18.629 0.043*
Negative expression (−) 4 (28.6) 14 (63.6)
Progesterone receptor
Positive expression (+) 9 (64.3) 5 (22.7) 6.12 1.394 26.876 0.016*
Negative expression (−) 5 (35.7) 17 (77.3)
*Fisher’s exact test: Statistically significant if p<0.05; OR: Odds ratio, PRB: Progesterone receptor, 
ER: Estrogen receptor.
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and E staining according to histopathological grade is 
shown in Figure 1. 
cba
Figure 1: The endometrioid-type ovarian carcinoma (HE, ×100) ([a] 
Grade 1; [b] Grade 2; [c] Grade 3)
The positive results of immunohistochemical 
ER staining are shown in Figures 2.
cba
Figure 2: Positive expression of estrogen receptor in endometrioid-
type ovarian carcinoma (IHK ER, ×400) ([a] Grade 1; [b] Grade 2; [c] 
Grade 3)
The positive results of immunohistochemical 
PR staining are shown in Figures 3.
cba
Figure 3: Positive expression of progesterone receptor in 
endometrioid-type ovarian carcinoma (IHK PR, ×400) ([a] Grade 1; 
[b] Grade 2; [c] Grade 3)
Discussion
Epithelial ovarian cancer is a heterogeneous 
disease, with various subtypes that differ in terms of 
cell origin, pathogenesis, molecular changes, gene 
expression, and prognosis. Endometrioid type is found 
around 10–20% of all ovarian carcinomas. The other 
types are high-grade serous (70%), clear cell (10%), 
mucinous (3%), and low-grade serous (<5%) [8], [9]. 
In our setting, based on initial study, the prevalence 
of endometrioid-type carcinoma was also the most 
common, around 15–25% among other types. Other 
studies found the incidence of endometrioid-type 
ovarian carcinoma only around 7–7.7%, while the other 
types are 70.5% serious type, 13.5% mucinous, and 
8.3% clear cell [6], [12].
A study by Lenhard et al. found that ovarian 
cancer occurred in the age range of 21–88 years at 
diagnosed, with an average age of 59 years [6]. In this 
study, the most age group was 41–50 years old (41.7%), 
younger than the previous study, but remains in the 
fifth decade. Based on the degree of differentiation, 
the most distinctive of ovarian cancer is Grade 2 as 
many as 36.5%, while Grade 1 and Grade 2 were found 
as many as 27.2% and 36.3%, respectively [6]. In a 
recent study, the most differentiation was also found in 
Grade 2 (38.9%).
Endometrioid-type ovarian carcinoma 
morphologically is similar to its counterpart in the 
endometrium, and about 50% is limited to the ovary 
at the time of diagnosis. In one study, the most stage 
is found in FIGO Stage III as many as 70.3% and 
then 22.6% Stage I, 5.8% Stage II, and 1.3% Stage 
IV [6]. Another study found that prognosis of ovarian 
carcinoma tends to be poor because the incidence of 
tumor at an advanced stage when the first diagnosis is 
quite high, which is about 75% of all patients showed 
FIGO Stage III or IV [2]. In this study, based on the size 
of the tumor, the most sample was T3 or FIGO Stage III 
as many as 15 samples (41.7%).
The previous study found that there were 
differences in ER and PR expression among various 
ovarian cancer subtypes. The highest proportion is the 
expression in endometrioid-type carcinomas many as 
67%, and the second is in low-grade serous carcinoma 
as many as 58%, the rest is 31% in high-grade serous 
carcinoma, 17% in mucinous carcinoma, and 8% in 
clear cell carcinoma [11]. A study by Sieh et al., in 2013, 
found that positive ER expressions were more than 
positive PR in all types of ovarian carcinoma. In tumors 
with positive ER expression and positive PR expression, 
the most expression was found in the endometrioid type 
which was as many as 82% [11]. In line with the previous 
study, George et al. found that a positive ER expression 
in epithelial ovarian cancer is also approximately 
occurred in 43–81% samples [13]. In another study, 
which examined the expression of ER and PR isoform 
(namely, ER-α, ER-β and PR-A, PR-B), it was found that 
ovarian carcinoma was positive for ER-α/-β by 31.4% 
and 60.1%; and positive for PR-A/-B by 36.2% and 
33.8%. It is similar to the results of another study, i.e. the 
expression of ER in ovarian cancer is by 32–77% and 
by 26–43% for PR expression [6]. The recent study also 
found a positive ER and PR expression in 18 samples 
(50%) and 14 samples (38.9%), respectively.
A previous study found that ER-α expression 
shows significant correlation with grade [2]. In this study, 
based on the degree of differentiation, the most positive 
ER expression was found in Grade 2 or below as many 
as 15 (65.2), while the most negative ER expression was 
found in Grade 3 as many as 10 samples (76.9%). Our risk 
analysis model found that ER expression was 6.25 times 
higher significantly in Grade 2 or below. A similar result 
also found on tumor size, whereas the most positive ER 
expression was found in T1 approximately 10 samples 
(71.4%), while the most negative ER expression was 
found in T2 or more, as many as 14 samples (63.6%). Our 
findings also exhibit that ER expression was 4.375 times 
higher significantly toward tumor size. The recent finding 
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suggests that the tumor size which is positively correlated 
to the grading of cancer also depicted a higher ER 
expression in ovarian type carcinoma.
Besides ER expression, our study also 
found a similar result with PR expression. The most 
positive PR expression was found in Grade 2 (50.0%), 
while the most negative PR expression was found 
in Grade 3 (54.5%). Our findings suggest that PR 
expression was predominantly higher on low grade and 
tumor size several times compared with the negative 
results (15.60 times higher to the degree of differentiation 
and 6.12 times higher to the tumor size). Those results 
are found after reclassified both parameters, degree of 
differentiation and tumor size.
A study conducted by Sieh et al. revealed that 
positive ER and PR expressions are associated with 
increased patient survival. Expression of ER and PR 
is prognostic biology marker in endometrioid type and 
high-grade serous type ovarian carcinoma. Patients with 
positive ER and PR expressions have lower mortality 
compared to those with negative hormonal expression. 
The clinical trial, determination of subtype, and status of 
biological marker are necessary to determine whether 
the hormonal receptor status can predict the response 
to endocrine therapy and whether it can be used to 
identify ovarian cancer therapy individually [6], [11]. 
The study by Halon et al. found that only 15–18% of 
ovarian cancer with positive ER expression responded 
to anti-estrogen treatment by inhibiting estrogen and 
ER binding, whereas this therapy was effective in 50% 
of breast cancer patients with positive ER expression. 
Based on these results, the clinician could use this 
finding to determine their clinical reasoning in therapy, 
whereas estrogen or progesterone replacement 
therapy may have a favorable outcome if provided to 
the earliest degree of differentiation or lower tumor size.
Conclusion
ER and PR were statistically significant 
predominantly expressed in the early degree of 
differentiation and low tumor size among patients with 
endometrioid-type ovarian cancer at Sanglah General 
Hospital, Bali, Indonesia. However, as a preliminary 
study, further investigation with a bigger sample size 
as well as a different design of study needs to be 
conducted to clarify the recent findings.
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